At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Subscribe To Our Newsletter & Stay Updated
